Patents Assigned to Pfizer
  • Cannabinoid receptor ligands and uses thereof
    Publication number: 20040214837
    Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.
    Type: Application
    Filed: April 12, 2004
    Publication date: October 28, 2004
    Applicant: Pfizer Inc.
    Inventors: David A. Griffith, Marlys Hammond
  • Cannabinoid receptor ligands and uses thereof
    Publication number: 20040214838
    Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.
    Type: Application
    Filed: April 12, 2004
    Publication date: October 28, 2004
    Applicant: Pfizer Inc
    Inventors: Philip A. Carpino, David A. Griffith
  • Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
    Publication number: 20040214843
    Abstract: The invention provides compounds which are PDE7inhibitors, having the following formula (I), (II) and (III) 1
    Type: Application
    Filed: May 24, 2004
    Publication date: October 28, 2004
    Applicant: Pfizer Inc
    Inventors: Patrick Bernardelli, Pierre Ducrot, Edwige Lorthiois, Febrice Vergne
  • Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof
    Patent number: 6809200
    Abstract: A process is provide for the preparation of compounds of formula (I) herein comprising reacting a compound of formula (III), (IV) or (V) wherein the variables are as defined in the specification. The reaction is conducted in the presence of −OR3 and a hydroxide trapping agent or in the case of compounds of formula (IV) reacting in the presence of an auxiliary base and a hydroxide trapping agent.
    Type: Grant
    Filed: July 26, 2001
    Date of Patent: October 26, 2004
    Assignee: Pfizer Inc.
    Inventors: Charlotte Moira Norfor Allerton, Christopher Gordon Barber, Keith Michael DeVries, Laurence James Harris, Philip Charles Levett, Joanna Teresa Negri, David James Rawson, Albert Shaw Wood
  • Pharmaceutical composition for the treatment of CNS and other disorders
    Patent number: 6809094
    Abstract: The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant &agr;7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant &agr;7 nicotinic receptor agonist.
    Type: Grant
    Filed: August 28, 2002
    Date of Patent: October 26, 2004
    Assignee: Pfizer Inc
    Inventors: Brian Thomas O'Neill, Jotham Wadsworth Coe, Christopher J. O'Donnell
  • Macrolide antibiotics
    Patent number: 6809080
    Abstract: This invention relates to compounds of the formula and to pharmaceutically acceptable salts, prodrugs, and solvates thereof wherein X, Y, R1, R2, R3, R4, and R6 are as defined herein. The compounds of formula I are antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula I, methods of making the compounds, and to methods of treating bacterial and protozoal infections by administering the compounds.
    Type: Grant
    Filed: June 26, 2001
    Date of Patent: October 26, 2004
    Assignee: Pfizer, Inc.
    Inventors: Takushi Kaneko, William Thomas McMillen
  • Solubilized sertraline compositions
    Publication number: 20040208926
    Abstract: Compositions of matter comprising sertraline and a solubilizing agent which increases the solubility of sertraline in aqueous chloride ion-containing use environments.
    Type: Application
    Filed: May 4, 2004
    Publication date: October 21, 2004
    Applicant: Pfizer Inc
    Inventors: Dwayne Thomas Friesen, Scott Max Herbig, Ravi Mysore Shanker, James Blair West
  • Method and system for forecasting resources for the development of pharmaceutical drugs
    Publication number: 20040210473
    Abstract: The method and system of the present invention is a Resource Forecasting Model (hereinafter “the RFM”). The RFM is a model of the Drug Development Process. More specifically, the RFM calculates Direct Project Resources for the development process of pharmaceutical drug Candidates, for a user-selected Forecast Period after initial discovery of the Candidates until final FDA regulatory approval thereof. The present invention provides a computer system with a database, a server, and a client. The client may be connected to the database and server via a direct connection, such as a local network, or via a web-based connection.
    Type: Application
    Filed: November 7, 2003
    Publication date: October 21, 2004
    Applicant: Pfizer Inc.
    Inventor: Daniel Goddard
  • Pyrrolo[1,2-B]pyridazine compounds and their uses
    Publication number: 20040209887
    Abstract: Disclosed are novel CRF receptor antagonists and their use as treatment of a variety of disorders, including disorders manifesting hypersecretion of CRF or associated with CRF or CRF receptors, such as anxiety, and depression.
    Type: Application
    Filed: March 12, 2004
    Publication date: October 21, 2004
    Applicant: Pfizer Inc
    Inventor: Jian-min Fu
  • Continuous-read assay for the detection of de novo HCV RNA polymerase activity
    Publication number: 20040209283
    Abstract: The invention provides a method for detecting RNA polymerase activity in a continuous-read manner. Specifically, the invention provides a method for detecting the de novo polymerase activity of the Hepatitis C virus (HCV) polymerase, NS5B, in a continuous-read manner. The invention also provides a method of screening for modulators of RNA polymerase activity. More specifically, the invention provides a method of screening for modulators of HCV NS5B activity.
    Type: Application
    Filed: November 13, 2003
    Publication date: October 21, 2004
    Applicant: Pfizer Inc.
    Inventors: Yoshihiko Yagi, Michael P. Sheets, Peter A. Wells, John A. Shelly, Roger A. Poorman, Dennis E. Epps, Aric G. Morgan
  • Pyrazole derivatives
    Publication number: 20040209862
    Abstract: This invention relates to the use of pyrazole derivatives of the formula 1
    Type: Application
    Filed: April 26, 2004
    Publication date: October 21, 2004
    Applicant: PFIZER, INC.
    Inventors: Romuald Gaston Corbau, Charles Eric Mowbray, Manoussos Perros, Paul Anthony Stupple, Anthony Wood
  • Combination therapies
    Publication number: 20040209916
    Abstract: The invention is directed to methods of treating asthma, COPD, allergic rhinitis, and infectious rhinitis by administering a first pharmaceutical agent including one or more compounds selected from the quarternary ammonium compounds of formulae I-V and a second pharmaceutical agent including one or more pharmaceutical agents selected from Adenosine A2a Receptor Agonists, D2-Dopamine Receptor Agonists, Phosphodiesterase Inhibitors (PDE's), corticosteroids, norepinephrine reuptake inhibitors, 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]-propylsulphonyl]ethylamino]ethyl]-1,3-benzothiazol-2(3H)-one, and pharmaceutically acceptable salts thereof, and non-quarternized antimuscarinic compounds.
    Type: Application
    Filed: April 13, 2004
    Publication date: October 21, 2004
    Applicant: Pfizer Inc
    Inventors: Ivan Michael Richards, Robert Everett Manning
  • 2-Azabicyclo[3.3.1]nonane derivatives
    Publication number: 20040204445
    Abstract: The subject invention relates to 2-azabicyclo[3.3.1]nonane derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat disease states, disorders and conditions mediated by opioid receptors. The subject invention also particularly relates to using such derivatives to treat certain disorders and conditions, for example irritable bowel syndrome, drug addiction, including alcohol addiction, depression, anxiety, schizophrenia and eating disorders, among others, as are more fully described herein.
    Type: Application
    Filed: January 22, 2004
    Publication date: October 14, 2004
    Applicant: Pfizer Inc.
    Inventors: Jotham W. Coe, Stanton McHardy
  • Pharmaceutical composition for the treatment of CNS and other disorders
    Publication number: 20040204416
    Abstract: The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant &agr;7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant &agr;7 nicotinic receptor agonist.
    Type: Application
    Filed: April 27, 2004
    Publication date: October 14, 2004
    Applicant: Pfizer Inc
    Inventors: Brian Thomas O'Neill, Jotham Wadsworth Coe, Christopher J. O'Donnell
  • Pyrrolo[1,2-B]pyridazine compounds and their uses
    Publication number: 20040204415
    Abstract: Disclosed are novel CRF receptor antagonists and their use as treatment of a variety of disorders, including disorders manifesting hypersecretion of CRF or associated with CRF or CRF receptors, such as anxiety, and depression.
    Type: Application
    Filed: March 12, 2004
    Publication date: October 14, 2004
    Applicant: Pfizer Inc
    Inventor: Jian-min Fu
  • 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors
    Publication number: 20040204453
    Abstract: The subject invention relates to 4-phenyl-piperidine derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat disease states, disorders and conditions mediated by an opioid receptor. The subject also particularly relates to using such derivatives to treat certain disease states, disorders and conditions, for example irritable bowel syndrome, drug addiction or dependency, including alcohol addiction, depression, anxiety, schizophrenia, anxiety, schizophrenia and eating disorders, among numerous other disease states, disorders and conditions as more fully described herein.
    Type: Application
    Filed: January 22, 2004
    Publication date: October 14, 2004
    Applicant: Pfizer Inc
    Inventors: Stanton McHardy, Spiros Liras, Sara Guediche, Jotham W. Coe
  • Uses of anti-insulin-like growth factor 1 receptor antibodies
    Publication number: 20040202651
    Abstract: The present invention relates to a therapeutic method comprising administering anti-IGF-IR antibodies, particularly human anti-IGF-IR antibodies to a subject for the treatment of certain disorders preferably in conjunction with administration of another therapeutic agent. The invention further relates to pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment.
    Type: Application
    Filed: February 10, 2004
    Publication date: October 14, 2004
    Applicant: Pfizer Inc.
    Inventors: Bruce D. Cohen, Vahe Bedian, Mihail Obrocea, Jesus Gomez-Navarro, John D. Cusmano, Huifen F. Wang, Deborah J. Guyot, Kelly L. Page
  • Quinoline and quinoxaline compounds
    Publication number: 20040204450
    Abstract: Quinoline and quinoxaline compounds, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
    Type: Application
    Filed: March 23, 2004
    Publication date: October 14, 2004
    Applicant: Pfizer Inc
    Inventors: Bruce M. Bechle, George C. Chang, Mary Didiuk, Jari I. Finneman, Ravi S. Garigipati, Ryan M. Kelley, David A. Perry, Roger B. Ruggeri
  • Pyrrolo[1,2-B]pyridazine compounds and their uses
    Publication number: 20040204414
    Abstract: Disclosed are novel CRF receptor antagonists and their use as treatment of a variety of disorders, including disorders manifesting hypersecretion of CRF or associated with CRF or CRF receptors, such as anxiety, and depression.
    Type: Application
    Filed: March 12, 2004
    Publication date: October 14, 2004
    Applicant: Pfizer Inc
    Inventor: Jian-min Fu
  • 2-amino-6-(2,4,5-substituted-phenyl)-pyridines
    Patent number: 6803470
    Abstract: The present invention relates to the compounds 6-[4-(N-methyl-3-azetidinoxy)-5-ethyl-2-methoxy-phenyl]-pyridin-2-ylamine, 6-[4-(N,N-dimethylaminomethyl)-5-ethyl-2-methoxy-phenyl]-pyridin-2-ylamine, 6-[4-(N-methylaminomethyl)-5-ethyl-2-methoxy-phenyl]-pyridin-2-ylamine and 6-[4-(3-azetidinoxy)-5-ethyl-2-methoxy-phenyl]-pyridin-2-ylamine, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing such compounds and to the use of such compounds in the treatment and prevention of central nervous system and other disorders.
    Type: Grant
    Filed: October 8, 2002
    Date of Patent: October 12, 2004
    Assignee: Pfizer Inc
    Inventors: John A. Lowe, III, Robert A. Volkmann